Health Affairs, 26, no. 3 (2007): 887-890 doi: 10.1377/hlthaff.26.3.887 © 2007 by Project HOPE	New Online   How Would Obama, McCain Cover The Uninsured?   Cost To Cover Uninsured   Let Health IT Market Evolve   How Rate Health IT Progress?   HIV/AIDS In India, China

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Lichtenberg, F. R. Search for Related Content PubMed Articles by Lichtenberg, F. R. Related Collections Consumer Issues Pharmaceuticals Research And Technology Health Spending

UpDate

PERSPECTIVE

Effects Of New Drugs On Overall Health Spending: Frank Lichtenberg Responds

When the model I estimated in 2002 is modified in all of the ways advocated by Yuting Zhang and Stephen Soumerai, it still implies that in general, using newer drugs reduces nondrug costs more than it increases drug costs. Moreover, some of Zhang and Soumerai’s modifications might be inappropriate, and they did not make a necessary adjustment that implies that the true cost offset is considerably larger than their estimate. Their description of my methodology is quite inaccurate, and they ignored some previous evidence of large cost offsets based on an entirely different methodology (analysis of longitudinal group-level data) not subject to their critique.

                      What's this?